2025 Q4 -tulosraportti
18 päivää sitten
‧1 t 3 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
34,25VWAP
Alin
33,7VaihtoMäärä
67,1 4 418 772
VWAP
Ylin
34,25Alin
33,7VaihtoMäärä
67,1 4 418 772
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 29.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenI follow Teva very closely, but I'm wondering and need help with the following: Is there an explanation for why Teva keeps going down, when Analyst Price Targets have - almost just - been raised to 45.00?·1 päivä sittenTEVA is just "resting" before the stock goes higher. See my long post from Nov 8, 2025. I have also described the price there based on TA. You can click on links and see charts.·1 päivä sittenTHANKS for the help UG with your great review of Teva. I also thought that a lot of good things had been written about the stock…hence my surprise. I own the stock and took some of the profit a while ago. Unfortunately, I MUST have sold the rest of Teva before d.1/4-25 and had limited it to $40, which I have now deleted, as it went down again and again. I am unfortunately quite pressured now pgraf the time interval and must of course have limited it again. I hope it soon takes off…also awaiting Druckenmiller Q4, which probably makes a positive impact. The pre-market looks PT not too good. 🤞😊
·28.1.Teva-Q4 2025 - Comments Due to work, unfortunately, I don't have time to listen to the conference call directly, but it can be read within 24 hours on Teva's website and will be interesting to read. Looking at the share price development throughout the day, I must admit I am somewhat surprised. Pre-Market was quite down, probably -4%+ and here 0.5 hour before closing 1.5% up, a spread between USD 30.95 and 33.03, approx. USD 2, that's a lot, turnover well 16.3 million shares. One can ask oneself if the financial report was bad, nah, rather on the good side, is the future bad, nah, are there any price triggers in the future, yes, several, and here I'm mostly thinking about Duvakitung phase 3 results, where phase 2 results were far above expectation, here is a potential Blockbuster. Furthermore, there are several products in the early phase for market rollout, and if they continue at the same pace in 2026, yes, most of it will go to the bottom line, and that's something we like. Have been invested since 2019 and have had many, as in many shares, so I have reduced by 1/3 through 2025 as it went completely crazy, but plan to keep the rest for a while, but will probably reduce at USD 45 and USD 55, which I think will happen before the end of 2027, because I think dividends will become relevant in 2028 when the agreement, as I understand it, with the Israeli authorities expires at the end of 2027, and with dividends, the share will become interesting for funds that have stable healthcare stocks that pay dividends, and then demand will slowly but surely increase, as I'm sure funds have Teva on their radar.
·30.1.No doubt it was a more obvious investment a couple of years ago. Now I see it more as slightly above average: TEVA's own goal is to increase free cash flow from $2.4 billion in 2025 to $3.5 billion in 2030. This corresponds to 8% annual growth. At the same time, they expect to reach debt/EBITDA of 2 in 2027 and will then potentially be able to return money to shareholders, so I immediately see an 8-10% annual return as realistic, as the current P/E of approx. 12 (I know Nordnet says 27 but they report an EPS of 2.65 when one does not include one-off incomes and has a share price of $33 which thus does not give 27) does not seem high. They can of course easily miss their targets but all in all, I still see a close to or slightly above market return with a slightly below market risk, as medicine is not the most volatile market and they are not dependent on a single blockbuster that risks being outcompeted by a better drug. I myself am up 215% and have not sold along the way but also started with a relatively small part of my portfolio invested in the company. I could sell but have other positions where I'd rather use the profit I can realize at a low tax rate, so I think I'll stay for now.·30.1.Now I write 8-10% return because I include the possibility the possibility of dividend (I am long-term so for me 2027 is not far into the future) and I write "close to or just above market return". That I would say 8-10% is. The historical average return has after all been 7-8%.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
18 päivää sitten
‧1 t 3 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenI follow Teva very closely, but I'm wondering and need help with the following: Is there an explanation for why Teva keeps going down, when Analyst Price Targets have - almost just - been raised to 45.00?·1 päivä sittenTEVA is just "resting" before the stock goes higher. See my long post from Nov 8, 2025. I have also described the price there based on TA. You can click on links and see charts.·1 päivä sittenTHANKS for the help UG with your great review of Teva. I also thought that a lot of good things had been written about the stock…hence my surprise. I own the stock and took some of the profit a while ago. Unfortunately, I MUST have sold the rest of Teva before d.1/4-25 and had limited it to $40, which I have now deleted, as it went down again and again. I am unfortunately quite pressured now pgraf the time interval and must of course have limited it again. I hope it soon takes off…also awaiting Druckenmiller Q4, which probably makes a positive impact. The pre-market looks PT not too good. 🤞😊
- ·28.1.Teva-Q4 2025 - Comments Due to work, unfortunately, I don't have time to listen to the conference call directly, but it can be read within 24 hours on Teva's website and will be interesting to read. Looking at the share price development throughout the day, I must admit I am somewhat surprised. Pre-Market was quite down, probably -4%+ and here 0.5 hour before closing 1.5% up, a spread between USD 30.95 and 33.03, approx. USD 2, that's a lot, turnover well 16.3 million shares. One can ask oneself if the financial report was bad, nah, rather on the good side, is the future bad, nah, are there any price triggers in the future, yes, several, and here I'm mostly thinking about Duvakitung phase 3 results, where phase 2 results were far above expectation, here is a potential Blockbuster. Furthermore, there are several products in the early phase for market rollout, and if they continue at the same pace in 2026, yes, most of it will go to the bottom line, and that's something we like. Have been invested since 2019 and have had many, as in many shares, so I have reduced by 1/3 through 2025 as it went completely crazy, but plan to keep the rest for a while, but will probably reduce at USD 45 and USD 55, which I think will happen before the end of 2027, because I think dividends will become relevant in 2028 when the agreement, as I understand it, with the Israeli authorities expires at the end of 2027, and with dividends, the share will become interesting for funds that have stable healthcare stocks that pay dividends, and then demand will slowly but surely increase, as I'm sure funds have Teva on their radar.·30.1.No doubt it was a more obvious investment a couple of years ago. Now I see it more as slightly above average: TEVA's own goal is to increase free cash flow from $2.4 billion in 2025 to $3.5 billion in 2030. This corresponds to 8% annual growth. At the same time, they expect to reach debt/EBITDA of 2 in 2027 and will then potentially be able to return money to shareholders, so I immediately see an 8-10% annual return as realistic, as the current P/E of approx. 12 (I know Nordnet says 27 but they report an EPS of 2.65 when one does not include one-off incomes and has a share price of $33 which thus does not give 27) does not seem high. They can of course easily miss their targets but all in all, I still see a close to or slightly above market return with a slightly below market risk, as medicine is not the most volatile market and they are not dependent on a single blockbuster that risks being outcompeted by a better drug. I myself am up 215% and have not sold along the way but also started with a relatively small part of my portfolio invested in the company. I could sell but have other positions where I'd rather use the profit I can realize at a low tax rate, so I think I'll stay for now.·30.1.Now I write 8-10% return because I include the possibility the possibility of dividend (I am long-term so for me 2027 is not far into the future) and I write "close to or just above market return". That I would say 8-10% is. The historical average return has after all been 7-8%.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
34,25VWAP
Alin
33,7VaihtoMäärä
67,1 4 418 772
VWAP
Ylin
34,25Alin
33,7VaihtoMäärä
67,1 4 418 772
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 29.1.2025 |
2025 Q4 -tulosraportti
18 päivää sitten
‧1 t 3 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 29.1.2025 |
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenI follow Teva very closely, but I'm wondering and need help with the following: Is there an explanation for why Teva keeps going down, when Analyst Price Targets have - almost just - been raised to 45.00?·1 päivä sittenTEVA is just "resting" before the stock goes higher. See my long post from Nov 8, 2025. I have also described the price there based on TA. You can click on links and see charts.·1 päivä sittenTHANKS for the help UG with your great review of Teva. I also thought that a lot of good things had been written about the stock…hence my surprise. I own the stock and took some of the profit a while ago. Unfortunately, I MUST have sold the rest of Teva before d.1/4-25 and had limited it to $40, which I have now deleted, as it went down again and again. I am unfortunately quite pressured now pgraf the time interval and must of course have limited it again. I hope it soon takes off…also awaiting Druckenmiller Q4, which probably makes a positive impact. The pre-market looks PT not too good. 🤞😊
- ·28.1.Teva-Q4 2025 - Comments Due to work, unfortunately, I don't have time to listen to the conference call directly, but it can be read within 24 hours on Teva's website and will be interesting to read. Looking at the share price development throughout the day, I must admit I am somewhat surprised. Pre-Market was quite down, probably -4%+ and here 0.5 hour before closing 1.5% up, a spread between USD 30.95 and 33.03, approx. USD 2, that's a lot, turnover well 16.3 million shares. One can ask oneself if the financial report was bad, nah, rather on the good side, is the future bad, nah, are there any price triggers in the future, yes, several, and here I'm mostly thinking about Duvakitung phase 3 results, where phase 2 results were far above expectation, here is a potential Blockbuster. Furthermore, there are several products in the early phase for market rollout, and if they continue at the same pace in 2026, yes, most of it will go to the bottom line, and that's something we like. Have been invested since 2019 and have had many, as in many shares, so I have reduced by 1/3 through 2025 as it went completely crazy, but plan to keep the rest for a while, but will probably reduce at USD 45 and USD 55, which I think will happen before the end of 2027, because I think dividends will become relevant in 2028 when the agreement, as I understand it, with the Israeli authorities expires at the end of 2027, and with dividends, the share will become interesting for funds that have stable healthcare stocks that pay dividends, and then demand will slowly but surely increase, as I'm sure funds have Teva on their radar.·30.1.No doubt it was a more obvious investment a couple of years ago. Now I see it more as slightly above average: TEVA's own goal is to increase free cash flow from $2.4 billion in 2025 to $3.5 billion in 2030. This corresponds to 8% annual growth. At the same time, they expect to reach debt/EBITDA of 2 in 2027 and will then potentially be able to return money to shareholders, so I immediately see an 8-10% annual return as realistic, as the current P/E of approx. 12 (I know Nordnet says 27 but they report an EPS of 2.65 when one does not include one-off incomes and has a share price of $33 which thus does not give 27) does not seem high. They can of course easily miss their targets but all in all, I still see a close to or slightly above market return with a slightly below market risk, as medicine is not the most volatile market and they are not dependent on a single blockbuster that risks being outcompeted by a better drug. I myself am up 215% and have not sold along the way but also started with a relatively small part of my portfolio invested in the company. I could sell but have other positions where I'd rather use the profit I can realize at a low tax rate, so I think I'll stay for now.·30.1.Now I write 8-10% return because I include the possibility the possibility of dividend (I am long-term so for me 2027 is not far into the future) and I write "close to or just above market return". That I would say 8-10% is. The historical average return has after all been 7-8%.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
34,25VWAP
Alin
33,7VaihtoMäärä
67,1 4 418 772
VWAP
Ylin
34,25Alin
33,7VaihtoMäärä
67,1 4 418 772
Välittäjätilasto
Dataa ei löytynyt